

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 February 2025 (13.02.2025)



(10) International Publication Number
WO 2025/032534 A9

(51) International Patent Classification:

A61K 39/00 (2006.01) *C07K 16/14* (2006.01)
A61K 39/39 (2006.01) *A61K 47/36* (2006.01)
A61P 31/10 (2006.01) *C12P 19/04* (2006.01)
C07K 14/40 (2006.01) *C12P 21/00* (2006.01)

(21) International Application Number:

PCT/IB2024/057693

(22) International Filing Date:

08 August 2024 (08.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/518,423 09 August 2023 (09.08.2023) US

(71) Applicant: **GLAXOSMITHKLINE BIOLOGICALS**

SA [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE).

(72) Inventors: **SERVENTI, Fabio**; c/o 1250 South Collegeville Road, Collegeville, Pennsylvania 19426 (US).
MARKOVIC-MULLER, Sandra; c/o 1250 South Collegeville Road, Collegeville, Pennsylvania 19426 (US).
LIPOWSKY, Gerd Martin; c/o 1250 South Collegeville Road, Collegeville, Pennsylvania 19426 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: MODIFIED PROTEINS




FIG. 2

(57) **Abstract:** The present invention relates to the field of modified proteins, immunogenic compositions and vaccines comprising the modified proteins, their manufacture and the use of such compositions in medicine. More particularly, it relates to a modified Als3 (Agglutinin-like sequence 3 of *Candida albicans*) protein. The modified Als3 protein can be used as a carrier protein for other antigens, particularly saccharide antigens or other antigens lacking T cell epitopes.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))*

(88) Date of publication of the international search report:
20 March 2025 (20.03.2025)

(48) Date of publication of this corrected version:
20 November 2025 (20.11.2025)

(15) Information about Correction:
see Notice of 20 November 2025 (20.11.2025)